Supportive Care in Cancer

, Volume 25, Issue 4, pp 1043–1044 | Cite as

Letter to the editor—chronic disseminated candidiasis

  • Kenneth RolstonEmail author
Letter to the editor

We read with interest the report by Pepa and colleagues regarding the management of chronic disseminated candidiasis (CDC) in patients with hematologic malignancies [1]. In their experience, only two of six patients (33%) with CDC responded to azole therapy, and only three (50%) received chemotherapy as planned, possibly having an adverse influence on the outcome of the underlying malignancy. In contrast, all six patients treated with high-dose liposomal amphotericin B (HD L-AmB) achieved complete resolution of CDC and only one had to interrupt the planned chemotherapy program. Patients receiving therapy with echinocandins also did not appear to do as well as those treated with HD L-AmB. Whilst the overall number of patients treated in this study was small and may have falsely exaggerated differences, this experience appears to be at odds with our clinical experience, as well as that of several other investigators who have reported response rates associated with azole therapy for CDC...


Compliance with ethical standards

Conflict of interest

The author declares that he has no conflict of interest.


  1. 1.
    Della Pepa R, Picardi M, Sorà F et al (2016) Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry. Support Care Cancer 24(9):3839–3845CrossRefGoogle Scholar
  2. 2.
    de Pauw BE, Raemaekers JM, Donnelly JP, Kullberg BJ, Meis JF (1995) An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol 70(2):83–87CrossRefGoogle Scholar
  3. 3.
    Kauffman CA, Bradley SF, Ross SC, Weber DR (1991) Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 91(2):137–141CrossRefGoogle Scholar
  4. 4.
    Anaissie E, Bodey GP, Kantarjian H et al (1991) Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91(2):142–150CrossRefGoogle Scholar
  5. 5.
    Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP (2000) Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin N Am 14(3):721–739CrossRefGoogle Scholar
  6. 6.
    Nace HL, Horn D, Neofytos D (2009) Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007. Diagn Microbiol Infect Dis 64(3):289–294CrossRefGoogle Scholar
  7. 7.
    Klotz SA, Chasin BS, Powell B, Gaur NK, Lipke PN (2007) Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn Microbiol Infect Dis 59(4):401–406CrossRefGoogle Scholar
  8. 8.
    Pulimood S, Ganesan L, Alangaden G, Chandrasekar P (2002) Polymicrobial candidemia. Diagn Microbiol Infect Dis 44(4):353–357CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Department of Infectious Disease, Infection Control and Employee HealthThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations